{"id":"bb-101","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3947713","moleculeType":"Small molecule","molecularWeight":"500.65"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BB-101 works by inhibiting the PI3K enzyme, which is involved in cell signaling and proliferation. This inhibition can lead to anti-tumor effects in various cancers.","oneSentence":"BB-101 is a small molecule that targets the PI3K pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:18.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT06383013","phase":"PHASE2","title":"BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers","status":"RECRUITING","sponsor":"Blue Blood Biotech Corp.","startDate":"2024-05-01","conditions":"Diabetic Foot Ulcer","enrollment":96},{"nctId":"NCT03888053","phase":"PHASE1","title":"BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers","status":"COMPLETED","sponsor":"Blue Blood Biotech Corp.","startDate":"2018-03-28","conditions":"Diabetic Foot Ulcer","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BB-101","genericName":"BB-101","companyName":"Blue Blood Biotech Corp.","companyId":"blue-blood-biotech-corp","modality":"Biologic","firstApprovalDate":"","aiSummary":"BB-101 is a small molecule that targets the PI3K pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}